{"id":775769,"date":"2023-08-07T06:34:02","date_gmt":"2023-08-07T10:34:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-highlights-recent-pipeline-and-business-progress-and-reports-second-quarter-2023-financial-results\/"},"modified":"2023-08-07T06:34:02","modified_gmt":"2023-08-07T10:34:02","slug":"annexon-highlights-recent-pipeline-and-business-progress-and-reports-second-quarter-2023-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annexon-highlights-recent-pipeline-and-business-progress-and-reports-second-quarter-2023-financial-results\/","title":{"rendered":"Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results"},"content":{"rendered":"
\n

\n ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward<\/em>\n <\/p>\n

\n Multiple Key Catalysts Expected in Second Half 2023, Including Completion of Enrollment in the Phase 3 Pivotal Trial of ANX005 in GBS and Phase 1 Data from ANX1502 Oral Small Molecule<\/em>\n <\/p>\n

\n Company to Provide Updates Across its Portfolio of Complement Therapies During R&D Day in Second Half 2023<\/em>\n <\/p>\n

\n Strong Financial Position with Operating Runway into 2025<\/em>\n <\/p>\n

BRISBANE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Annexon, Inc.<\/u><\/a> (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today highlighted recent progress across its business and portfolio of complement therapies and reported second quarter 2023 financial results.<\/p>\n

\u201cThis quarter, we made meaningful progress across our clinical-stage portfolio of medicines, which are squarely focused on stopping classical complement\u2019s aggressive inflammatory cascade where it starts on diseased tissue to provide the most complete protection against this harmful inflammation and its resulting damage,\u201d said Douglas Love, president and CEO of Annexon. \u201cFollowing our recent ARCHER data, we now have clinical proof-of-concept in three difficult-to-treat diseases: Guillain-Barr\u00e9 Syndrome (GBS), Huntington\u2019s disease and geographic atrophy (GA). Together, these data demonstrate the differentiated mechanism of inhibiting C1q to provide functional benefits for patients living with complement-mediated diseases. As we look ahead, we remain focused on executing toward important near-term milestones, including for our pivotal GBS program and oral small molecule program, in the second half of 2023. We look forward to providing additional updates on our progress and plans at our R&D Day later this year.\u201d<\/p>\n

\n Recent Corporate and Pipeline Updates<\/strong>\n <\/p>\n